Morphine Milligram Equivalent (MME) Calculator
Calculate daily morphine milligram equivalents (MME) from opioid prescriptions. CDC guidelines flag ≥50 MME/day as increased risk and ≥90 MME/day as high risk requiring careful justification and monitoring.
Why This Health Metric Matters
Why: MME enables risk assessment for overdose and guides prescribing decisions across multiple opioids.
How: Dose × conversion factor × frequency. Sum all opioids. Fentanyl patch: mcg/hr × 2.4.
- ●<50 MME: Continue monitoring
- ●50-89: Consider naloxone
- ●≥90: Avoid or justify carefully
📋 Quick Examples — Click to Load
Enter Opioid Medications
⚠️For informational purposes only — not medical advice. Consult a healthcare professional before acting on results.
🏥 Health Facts
CDC 2022 emphasizes individualized care. MME thresholds are risk indicators, not rigid limits.
— CDC 2022
What is Morphine Milligram Equivalent (MME)?
Morphine Milligram Equivalent (MME) is a standardized measure that expresses all opioid doses as equivalent doses of oral morphine. This standardization allows clinicians to assess total opioid exposure across multiple medications and forms, enabling better risk assessment for overdose and other adverse effects. The CDC 2022 Clinical Practice Guideline uses MME thresholds to guide prescribing decisions.
<50 MME/day
Lower risk threshold. Continue monitoring pain and function at each visit.
Recommendations:
- Regular reassessment
- Document benefit vs risk
- Consider non-opioid alternatives
50-89 MME/day
Increased overdose risk. Implement additional precautions and consider naloxone.
Recommendations:
- Co-prescribe naloxone
- PDMP check each visit
- Reassess pain management
≥90 MME/day
High risk. CDC recommends avoiding or carefully justifying doses at this level.
Recommendations:
- Document careful justification
- Evaluate for OUD
- Taper if possible
How to Calculate MME
Each opioid has a conversion factor that expresses its potency relative to oral morphine. Multiply the dose by the conversion factor and frequency to get daily MME. Sum all opioids for total daily MME.
📊 Calculation Example
Oxycodone 10mg QID + Hydromorphone 4mg TID
Oxycodone: 10mg × 1.5 × 4 = 60 MME/day
Hydromorphone: 4mg × 4 × 3 = 48 MME/day
Total Daily MME: 60 + 48 = 108 MME/day (HIGH RISK)
When to Calculate MME
MME calculation is a fundamental tool in opioid stewardship and should be performed routinely in several clinical scenarios to promote safe prescribing practices.
New Prescriptions
Before initiating or increasing opioids, calculate projected MME to assess risk.
Checkpoints:
- Initial opioid prescription
- Dose escalation requests
- Adding long-acting opioids
Multiple Opioids
When patients receive opioids from multiple prescribers or have multiple medications.
Risk Scenarios:
- Multiple prescribers
- Short + long-acting combo
- Post-surgical additions
PDMP Review
When reviewing prescription drug monitoring program data to assess total exposure.
Required By:
- Many state laws
- Before initial Rx
- At each refill
Naloxone Co-Prescribing Guidelines
Naloxone is an opioid antagonist that can reverse opioid overdose. The CDC recommends considering naloxone co-prescription when certain risk factors are present.
When to Co-Prescribe Naloxone
MME-Based Indications
- ≥50 MME/day - Consider naloxone
- ≥90 MME/day - Strongly recommend naloxone
- Any dose with concurrent benzodiazepine
Other Risk Factors
- History of overdose
- History of substance use disorder
- Renal or hepatic impairment
Dose Reduction Strategies
When MME exceeds thresholds or risks outweigh benefits, gradual dose reduction may be appropriate. Abrupt discontinuation should be avoided.
Gradual Taper
- 1Reduce by 5-10% every 4 weeks
- 2Pause taper if withdrawal symptoms severe
- 3Slower tapers for long-term therapy
- 4Monitor pain, function, and mood
Avoid Rapid Taper
- Can precipitate severe withdrawal
- May increase risk of illicit opioid use
- Associated with overdose deaths
- Harms patient-provider relationship
High-Risk Medication Combinations
Certain medication combinations dramatically increase overdose risk beyond what MME alone would predict. These combinations require careful evaluation and documentation.
FDA Black Box Warning: Opioids + Benzodiazepines
Concurrent use of opioids and benzodiazepines increases the risk of respiratory depression, overdose, and death. The FDA issued a black box warning in 2016.
Risk Statistics
- • 10x higher overdose risk
- • 30% of overdose deaths involve both
- • Risk increases at any dose level
Common Benzos
- • Alprazolam (Xanax)
- • Diazepam (Valium)
- • Clonazepam (Klonopin)
- • Lorazepam (Ativan)
If Must Use Together
- • Lowest effective doses
- • Shortest duration
- • Co-prescribe naloxone
- • Document justification
CDC 2022 Conversion Factors
| Opioid | Conversion Factor | Notes |
|---|---|---|
| Codeine | 0.15 | Oral |
| Fentanyl Patch | 2.4 | Transdermal (mcg/hr to MME/day) |
| Fentanyl (Buccal/SL) | 0.13 | Per mcg |
| Hydrocodone | 1 | Oral |
| Hydromorphone | 4 | Oral |
| Methadone (1-20 mg/day) | 4 | Oral 1-20mg/day |
| Methadone (21-40 mg/day) | 8 | Oral 21-40mg/day |
| Methadone (41-60 mg/day) | 10 | Oral 41-60mg/day |
*Methadone conversion is dose-dependent - higher doses require higher conversion factors
Special Considerations
Methadone Warning
Methadone has variable pharmacokinetics and dose-dependent conversion factors. Higher methadone doses require higher conversion ratios. Methadone prescribing requires specialized training.
Buprenorphine
Buprenorphine (Suboxone, Subutex) used for opioid use disorder is typically NOT counted toward MME as it's used for treatment, not pain management. Consult guidelines for specific situations.
CDC 2022 Clinical Practice Guideline Key Points
The 2022 CDC Clinical Practice Guideline for Prescribing Opioids updated the 2016 guideline with more flexible recommendations while maintaining safety focus.
No Rigid Thresholds
The 2022 guideline emphasizes that MME thresholds are not rigid limits, but risk indicators requiring careful evaluation.
Individualized Care
Decisions should be individualized based on specific patient circumstances, not applied rigidly to all patients.
Risk-Benefit Assessment
Reassess benefits and risks at each follow-up visit and before dose increases.
Avoid Sudden Discontinuation
Do not rapidly taper or discontinue opioids - this can harm patients and increase overdose risk.
Patient Collaboration
Decisions about opioid therapy should be made collaboratively with patients, not unilaterally by prescribers.
Multimodal Approach
Integrate non-opioid therapies (physical therapy, non-opioid medications, behavioral therapy) when possible.
MME Considerations in Special Populations
Elderly Patients
- • Increased sensitivity - lower MME thresholds apply
- • Reduced clearance prolongs duration
- • Higher fall and fracture risk
- • More drug interactions likely
- • Start at 25-50% of standard doses
Pregnancy
- • Chronic opioid use can cause neonatal withdrawal
- • MME doesn't predict fetal effects
- • Consider buprenorphine for OUD in pregnancy
- • Don't abruptly discontinue - can cause preterm labor
- • Multidisciplinary approach essential
Renal Impairment
- • Active metabolites accumulate (M6G for morphine)
- • Actual effect higher than calculated MME suggests
- • Prefer hydromorphone or fentanyl
- • Extend dosing intervals
- • Use lower thresholds for risk assessment
Mental Health Disorders
- • Higher overdose risk independent of MME
- • Depression/anxiety increase pain perception
- • Suicide risk assessment important
- • Concurrent psychiatric treatment often needed
- • Lower MME thresholds may be appropriate
Clinical Pearls for MME Assessment
Check PDMP First
Always check the prescription drug monitoring program before prescribing or calculating MME to capture all sources.
Document Reasoning
If prescribing above thresholds, document clear clinical justification and risk mitigation strategies.
Include All Sources
Calculate total MME from all opioid sources including PRN medications, even if not taken every day.
Conversion ≠ Exact
Equianalgesic conversions are estimates. Individual response varies - always start lower when rotating opioids.
High MME ≠ Abandon
Patients on high MME long-term need careful management, not abandonment. Rapid discontinuation causes harm.
Function Over Dose
Focus on functional improvement and quality of life, not just pain scores or dose levels.
Documentation Requirements
Proper documentation is essential for opioid prescribing compliance, risk management, and continuity of care. Document these elements at each opioid-related visit.
📋 Documentation Checklist
Assessment
- Current pain level and location
- Functional status assessment
- Current total daily MME
- PDMP review date and findings
Risk Evaluation
- Side effects present/absent
- Signs of misuse screening
- Urine drug test results if done
- Naloxone prescription status
Plan
- Justification for dose if >50 MME
- Non-opioid treatments considered
- Treatment agreement status
- Follow-up interval